The Optical Coherence Tomography Drug Eluting Stent Investigation (OCTDESI).
Phase of Trial: Phase II/III
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms OCTDESI
- Sponsors Boston Scientific Corporation
- 19 Apr 2011 Planned end date changed from 1 Mar 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 19 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jun 2009 Actual number of patients (60) added as reported by ClinicalTrials.gov.